Featured publications

• Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

  Villacampa, G; Tung, N M; Pernas, S; Pare, L; Bueno-Muino, C;

  (...)

  Carey, L A; Mittendorf, E A; Martin, M; Prat, A; Tolaney, S M.

  See complete list of authors

  Reference:

  Annals Of Oncology 2023.

• An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)

  Prat, A; Bardia, A; Curigliano, G; Viale, G; Hammond, MEH;

  Loibl, S; Tolaney, SM.

  Reference:

  Jama Oncology 2022.

• Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

  Prat, A; Brasó-Maristany, F; Sanfeliu, E; Schettini, F; Martínez, D;

  (...)

  Vivancos, A; Llombart-Cussac, A; Mira, A; Parker, JS; Perou, CM.

  See complete list of authors

  Reference:

  Ebiomedicine 2022.

• Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021

  H J Burstein; G Curigliano; B Thürlimann; W P Weber; P Poortmans 5;

  M M Regan; H J Senn; E P Winer; M Gnant; Panelists of the St Gallen Consensus Conference.

  Reference:

  Ann Oncol. 2021.

• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

  (...)

  Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

  See complete list of authors

  Reference:

  Journal Of Clinical Oncology 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  See complete list of authors

  Reference:

  Lancet Oncology 2020.

• Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  Martínez-Sáez, O; Chic, N; Pascual, T; Adamo, B; Vidal, M;

  (...)

  Muñoz, M; Prat, A; Martínez, D; Galván, P; Martinez, A.

  See complete list of authors

  Reference:

  Breast Cancer Research 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Brasó-Maristany, F; Griguolo, G; Pascual, T; Vidal, M; Adamo, B;

  (...)

  Manso, L; Alarcón, J; Martínez, E; Gregorio, S; Gomis, RR.

  See complete list of authors

  Reference:

  Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Prat, A; Saura, C; Pascual, T; Muñoz, M; Paré, L;

  (...)

  Hoyos, S; Rojas, B; Virizuela, JA; Ortega, V; López, R.

  See complete list of authors

  Reference:

  Lancet Oncology 2020.